Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionzinc ion binding

MDM2 ZFAND5 NFXL1 ZFAND6 ADAT2

1.90e-0589195GO:0008270
GeneOntologyMolecularFunctiontransition metal ion binding

MDM2 ZFAND5 NFXL1 ZFAND6 ADAT2

7.64e-05118995GO:0046914
HumanPhenoRhabdomyosarcoma

MDM2 CEP57

4.84e-052132HP:0002859
HumanPhenoNeoplasm of striated muscle

MDM2 CEP57

6.92e-052532HP:0009728
HumanPhenoStomach cancer

MDM2 CEP57

1.22e-043332HP:0012126
HumanPhenoAcute lymphoblastic leukemia

MDM2 CEP57

1.62e-043832HP:0006721
HumanPhenoColon cancer

MDM2 CEP57

1.71e-043932HP:0003003
HumanPhenoIntestinal polyposis

MDM2 CEP57

4.34e-046232HP:0200008
HumanPhenoIntestinal polyp

MDM2 CEP57

5.07e-046732HP:0005266
HumanPhenoNeoplasm of the colon

MDM2 CEP57

7.42e-048132HP:0100273
DomainZF_A20

ZFAND5 ZFAND6

4.33e-06792PS51036
DomainZnf_A20

ZFAND5 ZFAND6

4.33e-06792IPR002653
DomainZnF_A20

ZFAND5 ZFAND6

4.33e-06792SM00259
Domainzf-A20

ZFAND5 ZFAND6

4.33e-06792PF01754
DomainZnf_AN1

ZFAND5 ZFAND6

5.77e-06892IPR000058
Domain-

ZFAND5 ZFAND6

5.77e-068924.10.1110.10
DomainZnF_AN1

ZFAND5 ZFAND6

5.77e-06892SM00154
DomainZF_AN1

ZFAND5 ZFAND6

5.77e-06892PS51039
Domainzf-AN1

ZFAND5 ZFAND6

5.77e-06892PF01428
DomainZF_RING_1

MDM2 NFXL1

8.10e-0329192PS00518
DomainZF_RING_2

MDM2 NFXL1

8.48e-0329892PS50089
DomainZnf_RING

MDM2 NFXL1

1.01e-0232692IPR001841
Pubmed

Systematic identification of hepatocellular proteins interacting with NS5A of the hepatitis C virus.

CEP57 SFRP4

4.64e-06139215607035
Pubmed

Functional analysis of secreted and transmembrane proteins critical to mouse development.

MDM2 PTK7

2.76e-05319211431694
Pubmed

Wnt signaling in midbrain dopaminergic neuron development and regenerative medicine for Parkinson's disease.

SFRP4 PTK7

1.19e-04649224431302
GeneFamilyZinc fingers AN1-type|UPF1 like RNA helicases

ZFAND5 ZFAND6

2.57e-0686263
CoexpressionGSE22886_NAIVE_CD4_TCELL_VS_MEMORY_TCELL_DN

ZFAND6 CEP57 GBP1

3.55e-0520093M4412
ToppCell5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

NFXL1 ADAT2

4.79e-041669260060b03f2abfa3cc08107ab5a9f578e60e4ae16
ToppCell5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell-Goblet_(subsegmental)|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

NFXL1 ADAT2

4.79e-0416692ec9161d388db5a257b8d125c14f9dd911d5d5d4a
ToppCell5'-Parenchyma_lung-Epithelial-Epithelial_transtional-secretory-tracheobronchial_goblet_cell-Goblet_(subsegmental)-|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

NFXL1 ADAT2

4.79e-04166924586d6725403f879fc96f67be579022587ce1906
ToppCellfacs-Liver-Non-hepatocytes-3m-Myeloid-Kupffer_cell|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SFRP4 GBP1

4.96e-041699244d841fd997a6f26104f16cd00223ecce8352f43
ToppCell356C-Lymphocytic-CD8+_Cytotoxic_T-cell-CD8+_Cytotoxic_T_cell_1.5|CD8+_Cytotoxic_T-cell / Donor, Lineage, Cell class and subclass (all cells)

NFXL1 CEP57

4.96e-0416992b66ffc2b2b6bfcc3a6e639d9d31d3de95f4a94e1
ToppCelldroplet-Lung-18m-Hematologic-myeloid-classical_monocyte-classical_monocyte_l2-17-52|18m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

NFXL1 ADAT2

5.14e-0417292ebeda7ef181cac0109be750a98e7589c615d2724
ToppCell3'_v3-Lung-Myeloid_Monocytic-Cycling_mono|Lung / Manually curated celltypes from each tissue

NFXL1 PTK7

5.50e-041789267aa17b17da3121c199af45e747c23e2626a9bb2
ToppCellfacs-Lung-EPCAM-24m-Myeloid-Dendritic_Cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NFXL1 SFRP4

5.63e-04180925b7d2336ed09d07f6b8dd91c1fa9c5ade633c104
ToppCellfacs-Lung-24m-Hematologic-myeloid-myeloid_dendritic_cell-dendritic_cell|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

NFXL1 SFRP4

5.63e-0418092d33bb00f2b7d07dda9015cb8eafd742c2b2e9ace
ToppCell3'-Child04-06-SmallIntestine-Mesenchymal-fibroblastic-Stromal_4_(MMP1+)|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

SFRP4 PTK7

5.81e-0418392269afec240a756eec3bbae5f30ec784281af3433
ToppCellTCGA-Uvea-Primary_Tumor-Uveal_Melanoma-Epithelioid_Cell-4|TCGA-Uvea / Sample_Type by Project: Shred V9

MDM2 GBP1

5.88e-04184929c56753e5e668be888662e4713cf4ce44e6c58fb
ToppCell356C-Lymphocytic-CD4_T-cell-Treg_cell_2|CD4_T-cell / Donor, Lineage, Cell class and subclass (all cells)

MDM2 ADAT2

5.94e-0418592e06a784a297f357f3f8e761c24fa70722048ab42
ToppCell10x5'-bone_marrow-Myeloid_Dendritic-Cycling_Dendritic|bone_marrow / Manually curated celltypes from each tissue

SFRP4 PTK7

5.94e-04185929d3168c7f0b1d739f78b368969cf5c77ce202b97
ToppCell3'-Child04-06-SmallIntestine-Hematopoietic-Myeloid-Lymphoid_DC|Child04-06 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ZFAND5 GBP1

5.94e-041859248de4d9fad55077732bf64eca4919103ecbc1512
ToppCelltumor_Lymph_Node_/_Brain-Fibroblasts-Undetermined|Fibroblasts / Location, Cell class and cell subclass

GBP1 ADAT2

6.00e-0418692403ac98f72a42721f84fbd7826f251a88ae534a2
ToppCell3'-Adult-LargeIntestine-Mesenchymal-fibroblastic-mLN_Stroma_(FMO2+)|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract

ZFAND5 SFRP4

6.39e-041929211867f30f0b420c18cb0b34d3990237aa737a0e8
ToppCellCV-Severe-6|Severe / Virus stimulation, Condition and Cluster

ZFAND5 GBP1

6.53e-0419492d33be6ed1de907aeea0c2dce09796556b8efdd4e
ToppCellwk_20-22-Mesenchymal-Myofibro_&_SMC-Late_airway_SMC|wk_20-22 / Celltypes from embryonic and fetal-stage human lung

SFRP4 PTK7

6.59e-04195924dba732c8d8ecf0ed9ece1814dc4060402199ed9
ToppCellInt-URO-Myeloid-CD16_Mono|Int-URO / Disease, Lineage and Cell Type

ZFAND5 GBP1

6.66e-041969210772fed1471974cb49155df1da46e4016192620
ToppCellHealthy_Control-Myeloid-Macrophages-FCN1+SPP1+|Healthy_Control / Condition, Lineage, Cell class and cell subclass

MDM2 GBP1

6.80e-0419892aa90326b82e21de37af5642df6a70a8b21af7f04
ToppCellSmart-start-Cell-Wel_seq-Neoplastic-Differentiated-like-MES-like-MES-like_hypoxia/MHC-F|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group

SFRP4 GBP1

6.80e-0419892399760b6b6fef8639ded53b14f251b9fce600e81
ToppCellCOVID-19_Severe-PLT_4|COVID-19_Severe / Disease Group and Platelet Clusters

ZFAND5 ZFAND6

6.80e-0419892abfddbee99ef8c7719e6e6f62571e9be030e4acf
ToppCell(5)_Fibroblasts-(5)_Fibroblast-B_(Myofibroblast)|(5)_Fibroblasts / Lung cell shreds - cell class (v4) and cell subclass (v4)

SFRP4 PTK7

6.80e-0419892196257c4420ac801ed9fbb444f11718adb7560ae
ToppCell(04)_Interm._basal>secr.-(2)_GFP_FOXI1|(04)_Interm._basal>secr. / shred by cell type by condition

MDM2 ZFAND5

6.87e-041999253ca3861f9e00dab3f3fbefb0837857ee39ab084
ToppCellCOVID-19-COVID-19_Mild-Lymphocyte-T/NK-dn_T|COVID-19_Mild / Disease, condition lineage and cell class

GBP1 PTK7

6.87e-0419992f307d4887b28cf60a591439e278fd668409cb104
ToppCellILEUM-inflamed-(8)_Activated_fibroblasts|inflamed / shred on tissue, inflammation_status, cell class(v3), cell subclass (v2)

SFRP4 PTK7

6.87e-0419992317f412996d463ddf2e6a52ff41d5d676c77f43f
ToppCellLPS_IL1RA-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

SFRP4 PTK7

6.87e-04199926b3a0e5d52a30d0eed30e6a670f5b53bc233f70c
ToppCellLPS_only-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast|LPS_only / Treatment groups by lineage, cell group, cell type

SFRP4 PTK7

6.93e-0420092a9ff3210127000b3dd9e97136163c98c2b0817d7
ToppCell367C-Fibroblasts-Fibroblast-B_(Myofibroblast)|367C / Donor, Lineage, Cell class and subclass (all cells)

SFRP4 PTK7

6.93e-0420092731e55070a7ff315091855bd88cda30e5a7e1a98
ToppCell356C-Endothelial_cells-Endothelial-A_(Artery)-|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)

MDM2 ZFAND5

6.93e-0420092fa99901388eec28004bef85d84f0d7d5bd4df4a8
ToppCellSepsis-Int-URO-Myeloid-CD16+_Monocyte|Int-URO / Disease, condition lineage and cell class

ZFAND5 GBP1

6.93e-04200923f7fcf55d875cad8f99224d8e4f29eea8308fc8c
ToppCellLPS_IL1RA_TNF-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

SFRP4 PTK7

6.93e-042009209537dc25f8b8b4654a7c183827ee1522a41a4e0
ToppCell367C-Fibroblasts-Fibroblast-B_(Myofibroblast)-|367C / Donor, Lineage, Cell class and subclass (all cells)

SFRP4 PTK7

6.93e-0420092082e718c1da3f4fdd33a001d15ad3ddb2be985c7
ToppCell356C-Endothelial_cells-Endothelial-A_(Artery)|Endothelial_cells / Donor, Lineage, Cell class and subclass (all cells)

MDM2 ZFAND5

6.93e-042009289eae23195d57f1b23a337ff19c9b8a367e22c96
ToppCellControl_saline-Mesenchymal_myocytic-Myofibroblastic-MatrixFB_->_Myofibroblast|Control_saline / Treatment groups by lineage, cell group, cell type

SFRP4 PTK7

6.93e-0420092a799fc7bb83ad0524362cb5010df949741fb7bf3
DrugSulfisoxazole [127-69-5]; Up 200; 15uM; MCF7; HT_HG-U133A

MDM2 SFRP4 GBP1

5.08e-05196935622_UP
DrugPropoxycaine hydrochloride [550-83-4]; Up 200; 12uM; MCF7; HT_HG-U133A

MDM2 SFRP4 PTK7

5.24e-05198933583_UP
DrugVerapamyl hydrochloride [152-11-4]; Up 200; 8.2uM; MCF7; HT_HG-U133A

MDM2 SFRP4 GBP1

5.31e-05199931509_UP
DrugP-N-C

MDM2 ADAT2

2.35e-045992CID000449243
DrugAC1L9FY1

MDM2 ADAT2

6.87e-0410192CID000444218
Drugnonylphenol

ZFAND5 ZFAND6 GBP1

7.33e-0448593ctd:C025256
Drugglycylglycine

MDM2 PTK7

9.36e-0411892CID000011163
Drugpropidium iodide

MDM2 ADAT2

1.53e-0315192CID000004939
Drug15d-PGJ2; Up 200; 10uM; MCF7; HT_HG-U133A_EA

MDM2 ZFAND5

1.69e-03159921011_UP
Drug15d-PGJ2; Up 200; 10uM; MCF7; HT_HG-U133A_EA

MDM2 ZFAND5

1.75e-03162921069_UP
Drug15d-PGJ2; Up 200; 10uM; MCF7; HT_HG-U133A

MDM2 ZFAND5

1.91e-03169926948_UP
DrugNifuroxazide [965-52-6]; Up 200; 14.6uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.11e-03178922850_UP
Druggeldanamycin; Up 200; 1uM; MCF7; HT_HG-U133A_EA

MDM2 GBP1

2.20e-03182921008_UP
DrugDisulfiram [97-77-8]; Up 200; 13.4uM; PC3; HT_HG-U133A

ZFAND5 GBP1

2.23e-03183922053_UP
Drugprostaglandin E2; Up 200; 10uM; PC3; HT_HG-U133A

MDM2 PTK7

2.23e-03183926547_UP
DrugMephentermine hemisulfate [1212-72-2]; Up 200; 9.4uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.28e-03185924707_UP
DrugDiflorasone Diacetate [33564-31-7]; Up 200; 8uM; HL60; HT_HG-U133A

MDM2 SFRP4

2.28e-03185922142_UP
DrugMetixene hydrochloride [1553-34-0]; Up 200; 11.6uM; PC3; HT_HG-U133A

MDM2 SFRP4

2.30e-03186926672_UP
DrugSecurinine [5610-40-2]; Up 200; 18.4uM; MCF7; HT_HG-U133A

MDM2 ZFAND5

2.30e-03186926831_UP
DrugMethotrexate [59-05-2]; Up 200; 8.8uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.33e-03187925419_UP
DrugDehydroisoandosterone 3-acetate [853-23-6]; Up 200; 12.2uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.35e-03188925019_UP
DrugEtoposide [33419-42-0]; Up 200; 6.8uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.35e-03188923241_UP
Druggeldanamycin; Up 200; 1uM; MCF7; HG-U133A

MDM2 CEP57

2.37e-0318992611_UP
DrugHarmine hydrochloride [343-27-1]; Up 200; 16uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.40e-03190927209_UP
DrugChloroquine diphosphate [50-63-5]; Down 200; 7.8uM; MCF7; HT_HG-U133A

MDM2 CEP57

2.40e-03190922869_DN
DrugGramine [87-52-5]; Up 200; 23uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.45e-03192922799_UP
Drug0317956-0000 [391210-11-0]; Up 200; 1uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.45e-03192923858_UP
DrugDizocilpine maleate [77086-22-7]; Down 200; 11.8uM; MCF7; HT_HG-U133A

MDM2 CEP57

2.45e-03192926223_DN
DrugRaloxifene hydrochloride [82640-04-8]; Up 200; 7.8uM; HL60; HT_HG-U133A

MDM2 GBP1

2.45e-03192922738_UP
DrugQuinacrine dihydrochloride dihydrate [6151-30-0]; Up 200; 7.8uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.45e-03192923179_UP
DrugCP-944629 [668990-94-1]; Down 200; 10uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.47e-03193927497_DN
DrugPodophyllotoxin [518-28-5]; Up 200; 9.6uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.47e-03193926103_UP
DrugTropicamide [1508-75-4]; Down 200; 14uM; PC3; HT_HG-U133A

MDM2 GBP1

2.47e-03193924280_DN
DrugICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A

MDM2 PTK7

2.47e-03193927490_UP
Drugwortmannin from Penicillium funiculosum; Up 200; 0.01uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.47e-03193925603_UP
DrugPhenylpropanolamine hydrochloride [154-41-6]; Down 200; 21.4uM; PC3; HT_HG-U133A

MDM2 PTK7

2.47e-03193926699_DN
DrugIohexol [66108-95-0]; Down 200; 4.8uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.47e-03193923322_DN
DrugMethoxy-8-psoralen [298-81-7]; Up 200; 18.6uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.50e-03194923302_UP
DrugSisomicin sulfate [53179-09-2]; Down 200; 2.8uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.50e-03194924132_DN
DrugMetoclopramide monohydrochloride [7232-21-5]; Down 200; 11.8uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.50e-03194923625_DN
DrugDehydroisoandosterone 3-acetate [853-23-6]; Up 200; 12.2uM; PC3; HT_HG-U133A

MDM2 SFRP4

2.50e-03194926673_UP
DrugOxethazaine [126-27-2]; Up 200; 8.6uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.50e-03194924829_UP
DrugAltretamine [654-05-6]; Down 200; 19uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.50e-03194926467_DN
DrugLobelanidine hydrochloride [6112-86-3]; Up 200; 10.6uM; MCF7; HT_HG-U133A

SFRP4 PTK7

2.53e-03195922897_UP
DrugFurazolidone [67-45-8]; Up 200; 17.8uM; PC3; HT_HG-U133A

MDM2 GBP1

2.53e-03195924098_UP
DrugPicrotoxinin [17617-45-7]; Down 200; 13.6uM; PC3; HT_HG-U133A

MDM2 PTK7

2.53e-03195924260_DN
Drugaspirin, USP; Up 200; 100uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.53e-03195925564_UP
DrugFenbufen [36330-85-5]; Down 200; 15.8uM; MCF7; HT_HG-U133A

SFRP4 GBP1

2.53e-03195922308_DN
DrugHomocysteine

MDM2 ZFAND6

2.53e-0319592ctd:D006710
DrugPentoxifylline [6493-05-6]; Up 200; 14.4uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.53e-03195922290_UP
DrugFillalbin [4540-25-4]; Up 200; 13.8uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.53e-03195924172_UP
Drug(S)-propranolol hydrochloride [4199-10-4]; Up 200; 13.6uM; MCF7; HT_HG-U133A

MDM2 PTK7

2.53e-03195925444_UP
DrugAcenocoumarol [152-72-7]; Up 200; 11.4uM; PC3; HT_HG-U133A

MDM2 PTK7

2.53e-03195925878_UP
DrugChelidonine monohydrate (+) [476-32-4]; Up 200; 10.8uM; PC3; HT_HG-U133A

MDM2 GBP1

2.53e-03195925760_UP
DrugImidurea [39236-46-9]; Up 200; 10.4uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.53e-03195923522_UP
DrugMinaprine dihydrochloride [25953-17-7]; Up 200; 10.8uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.53e-03195924814_UP
DrugOleandomycin phosphate [7060-74-4]; Up 200; 5uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.53e-03195925676_UP
DrugMetrizamide [31112-62-6]; Down 200; 5uM; MCF7; HT_HG-U133A

MDM2 SFRP4

2.53e-03195924156_DN
DrugMethazolamide [554-57-4]; Up 200; 17uM; HL60; HT_HG-U133A

MDM2 GBP1

2.53e-03195922733_UP
DrugBromopride [4093-35-0]; Down 200; 11.6uM; PC3; HT_HG-U133A

MDM2 PTK7

2.53e-03195923719_DN
DrugCapsaicin [404-86-4]; Down 200; 13uM; HL60; HT_HG-U133A

MDM2 GBP1

2.53e-03195923034_DN
DrugReserpine [50-55-5]; Up 200; 6.6uM; PC3; HT_HG-U133A

SFRP4 PTK7

2.53e-03195924203_UP
DrugMolindone hydrochloride [15622-65-8]; Up 200; 12.8uM; MCF7; HT_HG-U133A

GBP1 PTK7

2.55e-03196927337_UP
DrugBeclomethasone dipropionate [5534-09-8]; Down 200; 7.6uM; PC3; HT_HG-U133A

MDM2 SFRP4

2.55e-03196924580_DN
Drugrosiglitazone; Up 200; 10uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.55e-03196925593_UP
DrugPyrazinamide [ 98-96-4]; Up 200; 32.4uM; HL60; HT_HG-U133A

MDM2 SFRP4

2.55e-03196922478_UP
DrugHydroflumethiazide [135-09-1]; Up 200; 12uM; MCF7; HT_HG-U133A

MDM2 GBP1

2.55e-03196921687_UP
DrugEdrophonium chloride [116-38-1]; Up 200; 19.8uM; PC3; HT_HG-U133A

MDM2 SFRP4

2.55e-03196926655_UP
DiseaseAdenocarcinoma of large intestine

MDM2 PTK7

3.72e-049692C1319315
DiseaseProstatic Neoplasms

MDM2 ZFAND5

1.42e-0261692C0033578
DiseaseMalignant neoplasm of prostate

MDM2 ZFAND5

1.42e-0261692C0376358

Protein segments in the cluster

PeptideGeneStartEntry
PNAPKSKVRKKECQK

ADAT2

176

Q7Z6V5
PCVPNARRIKKKKSK

CEP57

251

Q86XR8
CKKAKPIPRRCSAKE

NFXL1

291

Q6ZNB6
PCKRIKKELQCNKVR

NFXL1

801

Q6ZNB6
LPRLCIRKFFPKKKC

GBP1

221

P32455
KKLKKRNKPCPVCRQ

MDM2

466

Q00987
LPKPKKNRCFMCRKK

ZFAND5

146

O76080
KRLSPDRCKCKKVKP

SFRP4

171

Q6FHJ7
KPKQKKNRCFMCRKK

ZFAND6

141

Q6FIF0
CKKRCKAKRLQKQPE

PTK7

726

Q13308